TP53 and cancer: Integrating results from the studies described above for the different cancer types, it becomes clear that the most studied pathways targeted by SETD7 were regulated by the retinoblastoma-associated protein (pRb) and transcription factor E2F1 (E2F-1), both under normal conditions and upon treatment with DNA-damaging agents in p53 null or wild-type backgrounds (Figure 5).